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The contribution of genetic variants to sporadic amyotrophic lateral sclerosis (ALS) remains largely
unknown. Either recessive or de novo variants could result in an apparently sporadic occurrence of ALS.
In an attempt to find such variants we sequenced the exomes of 44 ALS-unaffected-parents trios. Rare
and potentially damaging compound heterozygous variants were found in 27% of ALS patients,
homozygous recessive variants in 14% and coding de novo variants in 27%. In 20% of patients more
than one of the above variants was present. Genes with recessive variants were enriched in nucleotide
binding capacity, ATPase activity, and the dynein heavy chain. Genes with de novo variants were
enriched in transcription regulation and cell cycle processes. This trio study indicates that rare private
recessive variants could be a mechanism underlying some case of sporadic ALS, and that de novo
mutations are also likely to play a part in the disease.
A
n intensive search for genetic disorders that could underlie amyotrophic lateral sclerosis (ALS) has
uncovered pathogenetic variants in about 10% of sporadic ALS (SALS) and 60% of familial ALS
(FALS) patients1. While this represents remarkable progress in only a few years, a major question is
whether most SALS arises from environmental factors, genetic predisposition, or some combination of the two.
Attempts have beenmade to look for environmental factors or gene-environment interactions underlying ALS in,
for example, pesticide exposure2, but despite work from many research groups no convincing environmental
factor for ALS has been found. Furthermore, numerous genome-wide association studies (GWAS) have revealed
no reproducible findings of common variants that would lead to ALS susceptibility in a substantial proportion of
patients3. There could be a number of reasons for such negative results in GWAS, one being a mismatch of
exposure to environmental factors and the presence of susceptibility genes.While there may be an environmental
contribution to SALS, the genetic contribution could comemostly from rare variants, which still allows for strong
gene-environment interactions.
If SALS has a strong genetic component, consideration needs to be given to the genetic mechanisms that could
be responsible for the sporadic occurrence of most cases of ALS. One form of inheritance that can give rise to an
apparently sporadic condition, especially in small families, is that of recessive variants4. Homozygous variants in
ALS have already been described in SOD1, OPTN, and FUS1, and other rare variants could be responsible to
further SALS cases4. Recessive inheritance due to rare compound heterozygous variants is another genetic
mechanism that can give rise to a sporadic disorder, since both rare variants are unlikely to be reproduced in
the next generation. It has often been pointed out that with the demographic shift to smaller families, a disease
with a recessive inheritance or with a low penetrance will seem sporadic in a large number of cases5.
De novomutation, in which the pathogenetic variant arises for the first time in the offspring of normal parents,
is a further mechanism that can give rise to an apparently sporadic disorder.De novomutations in FUS6, ERBB47
and ATXN28 have previously been suggested to be associated with ALS.
A powerful method of looking for recessive and de novo variants underlying a sporadic disorder is the use of
case-unaffected-parents trios. Large numbers of these trios are difficult to collect inALS, since it is unusual to have
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genome-wide copy number analysis of 12 SALS trios found a number
of de novo copy number variants (CNVs) in the SALS offspring; 11 of
these CNVs involved genes, some of which were in pathways sus-
pected in the pathogenesis of ALS9.More recently, exome sequencing
of 47 SALS trios brought to light de novo single nucleotide variants in
genes that may be involved in the pathogenesis of ALS10.
In an attempt to uncover rare recessive and de novo variants that
could underlie SALS, we therefore sequenced the exomes of 44
Australian case-unaffected-parents trios.
Results
ALS offspring patients and unaffected parents. White blood cell
DNA samples were available from 44 trios (see Table 1 for the
number of recessive and de novo variants found in each ALS
patient, and Supplementary Table S1 online for further clinical
details of the patients and all ages). Thirty-seven of the offspring
had classical sporadic ALS (SALS) with upper and lower motor
neuron signs, three had sporadic progressive muscular atrophy
(SPMA), two had sporadic progressive bulbar palsy (SPBP), one
had sporadic primary lateral sclerosis (SPLS), and one had
sporadic frontotemporal degeneration with motor neuron disease
(SFTD-MND).
The average age of disease onset of our ALS trio (ALSTRIO) off-
spring was 46.1 y (SD 9.1 y, range 26–63 y). In comparison, the
average age of disease onset for the 828 SALS patients in the
Australian MND DNA Bank was 61.9 y (SD 11.5 y, range 26–99
y), a significant difference on unpaired two-tailed t-testing (p ,
0.0001).
The average age of fathers at the birth of ALSTRIO offspringwas 29.4
y (SD 5.1 y, range 22–42 y) and that of the 689 AustralianMNDBank
fathers at ALS offspring birth was 31.4 y (SD 6.9 y, range 15–67 y), a
non-significant difference on t-testing (p5 0.06). The average age of
Table 1 | Clinical details and numbers of recessive and de novo variants detected in ALS trio patients













#01 Male ALS 44
#02 Female ALS 49 2 2
#03 Female ALS 35 3
#04 Female ALS 26 4
#05 Female ALS 50 1 4
#06 Male ALS 36 3 C9orf72 F
#07 Male ALS 36 3
#08 Female PMA 51 2 3
#09 Male ALS 53 4
#10 Male ALS 44 1 3
#11 Female ALS 53 1 3
#12 Female PBP 58 1 4
#13 Male ALS 53 1 na
#14 Male ALS 27 2 1 na
#15 Male ALS 35 1 na SOD1 F
#16 Male FTDMND 58 1 na
#17 Male ALS 51 na
#18 Female ALS 47 na
#19 Male ALS 53 1 na TDP-43 M
#20 Male ALS 56 4 1 na
#21 Male ALS 45 1 na
#22 Male ALS 46 1 na
#23 Male ALS 44 1 na
#24 Male ALS 36 2 2 na
#25 Female ALS 42 na
#26 Male ALS 41 1 na
#27 Male ALS 47 na
#28 Male PMA 55 na
#29 Female PBP 55 na
#30 Male ALS 50 1 2 na
#31 Female ALS 53 na
#32 Male ALS 57 na
#33 Male ALS 42 na
#34 Male ALS 48 na
#35 Male ALS 46 2 na C9orf72 F
#36 Male ALS 59 1 na
#37 Male ALS 28 na
#38 Female ALS 45 na
#39 Female ALS 53 1 na
#40 Female ALS 63 na
#41 Male ALS 37 1 1 na
#42 Male ALS 30 1 1 na
#43 Female PLS 45 1 na
#44 Male ALS 46 na
The ALS trio patients had a younger average age than usual for ALS. Most patients had classical ALS. Included in the table are de novoCNVs from 12 of the patients that were found in a previous study9. Four
ALS trio patients who had known ALS-associated mutations also had recessive or de novo variants. CNV: copy number variant. F: mutation also found in father, M: mutation also found in mother, na: not
applicable.
www.nature.com/scientificreports
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mothers at the birth of ALSTRIO offspring was 26.3 y (SD 4.0 y, range
20–38) and that of the 689 Australian MND Bank mothers at ALS
offspring birth was 28.2 y (SD 6.1 y, range 13–50 y), also a non-
significant difference on t-testing (p 5 0.05).
Total numbers of variants. The whole exomes of the 44 trios were
sequenced to an average of 52.5X coverage (see Methods and
Supplementary Methods online for sequencing details). A total of
307,780 variants passed false-positive and site filters, and 305,622
variants passed Hardy-Weinberg Equilibrium tests (p , 0.0001).
An average of 55,727 variants per individual was found (which
included a 500 bp wingspan from the target space that added an
additional 200 kbp of non-coding space with off-target variant
calling). Transition/Transversion (Ts/Tv) ratios for coding and
non-coding bases per individual (to assess the accuracy of single
nucleotide variant filtering), and replacement to silent ratios per
individual (to infer the direction and magnitude of natural
selection acting on protein coding genes), are available online in
Supplementary Tables 2 and 3, respectively.
Homozygous and compound heterozygote recessive variants. The
carrier rate of a potential recessive allele is estimated to be
approximately 1% based on an incidence of 2 per 100,000 per year.
Out of 16,866 unique autosomal recessive loss of function and
nonsynonymous variants, 90 were at global minor allele frequency
(MAF) , 1%. Out of 125,006 loss of function and nonsynonymous
compound heterozygous, 5,008 were at global MAF, 1%. For these
calculations, we required that the transmitted allele in both parents
was MAF , 1%. After rigorous filtering based on global MAF,
predicted functional consequence, and sequence conservation (for
Figure 1 | Filtering schema for exome variant calls in case-unaffected parents trios. (1) To identify autosomal recessive and compound heterozygous
variants (left track), variants were called using the unique union of VarScan and SAMtools calls. The trio was phased using BEAGLE v4 software and
annotated using the NCBI single nucleotide polymorphism database (dbSNP) and Variant Effect Predictor (VEP). Ingenuity variant analysis (IVA) and
Genome Mining (GEMINI) software were then used to rigorously filter variants based on quality, minor allele frequency, deleteriousness, inheritance
patterns, conservation and involvement inmotor neuron pathways (see SupplementaryMethods for parameters). The unique union of these variants was
manually reviewed and independently validated using Sanger sequencing. (2) To identify de novo variants (right track), variants were called using
Polymutt, a pedigree-aware variant caller. Phasing and annotation were as per the autosomal recessive and compound heterozygous variants. Variants
were then filtered and manually reviewed to eliminate systematic false positives. The remaining variants were validated with Sanger sequencing.
www.nature.com/scientificreports
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pathways see Figure 1), 49 recessive and compound heterozygous
variants remained for validation and further analysis. Full lists of
the coding recessive and compound heterozygous variants detected
are shown in Supplementary Dataset 1 and Supplementary Dataset 2
respectively online. We validated 28 compound heterozygous variants
in 19 different genes (Table 2), which involved 12 (27%) ALSTRIO
patients (Table 1). In 6 (14%) ALSTRIO patients 9 homozygous
recessive variants in 9 different genes were found (Tables 1 and 2).
The deleterious nature of these recessive variants can be judged from
their average SIFT score of 0.0058 and average PolyPhen2 score of
0.0008. A quarter of the genes with these recessive variants have
significantly increased expression in the spinal cord compared to
non-central nervous system tissues11 (Table 2).
De novo variants. Eighty-one de novo variants passedmanual review
in IGV and 54 were validated with Sanger sequencing (Figure 1). See
Supplementary Table S4 online for the complete list of de novo
variants. Seventeen of the de novo variants were coding, involving
12 (27%) ALSTRIO patients (Tables 1 and 3). Of these 17 variants, 15
were missense (10 identified as deleterious or damaging using SIFT,
PolyPhen and Condel), one splice site, and one nonsense. Twenty-
four percent of the genes in which we found de novo variants have
significantly increased expression in the spinal cord compared to
non-central nervous system tissues11 (Table 3). Although two
coding de novo variants were found in five ALSTRIO patients, the
distribution of de novo variants followed a Poisson distribution
(see Supplementary Fig. S1 online), indicating that multiple de
novo alleles in any one individual are unlikely to contribute to ALS
risk.
Relation of variants found to known ALS variants. The frequency
of variants in ALS susceptibility genes and the frequency of known
ALS susceptibility variants were assessed in our cohort using
ALSoD12. No increased burden of coding variants in known ALS
genes was found in this cohort. All of the coding variants have
been previously identified, and the alternate allele frequencies of
these variants are similar to those in the NHLBI ESP and the 1000
Genomes Project, with the exception of a few non-synonymous
variants that had elevated frequencies (see Supplementary Table S5
for a list of these). Given our limited sample size, however, we were
unable to determine whether this enrichment was statistically
significant.
Homozygous segments. No statistically significant enrichment of
homozygous segments was found by size, burden, or genomic
location in ALSTRIO patients versus controls.
Table 2 | Recessive homozygous or compound heterozygous variants in ALS trio patients













ABCA2 #24 9 139908464 Cpd Het Missense V1422F 0.008303 0.01 rs147917446 Up***
ABCA2 #24 9 139916347 Cpd Het Missense M224K NR NR NR Up****
ATP8B3 #16 19 1788909 Cpd Het Missense G1019D 0.003602 0 rs202137046 Down*
ATP8B3 #16 19 1796751 Cpd Het Missense C524Y NR NR NR Down*
CACNA1H #14 16 1265267 Cpd Het Missense V1683M NR NR NR Down**
CACNA1H #14 16 1265315 Cpd Het Missense A1699T 0.006668 0.0041 rs148651456 Down**
CNGA4 #24 11 6261613 Cpd Het Missense G197R NR NR NR ND
CNGA4 #24 11 6261718 Cpd Het Missense V232M NR NR NR ND
DENND2C #20 1 115130508 Homozygous Missense Y833H; Y776H 0.004075 0.0023 rs61753528 Down**
DNAH10 #23 12 124323006 Cpd Het Missense M1518V 0.009286 0.0027 rs145483216 Up**
DNAH10 #23 12 124409693 Cpd Het Missense R3837C 0.002361 0.0027 rs144421774 Up**
DNAH2 #41 17 7727209 Cpd Het Missense R3757H NR NR NR ND
DNAH2 #41 17 7734055 Cpd Het Missense G4003V NR NR NR ND
DNAH9 #26 17 11775004 Cpd Het Missense L1963F NR NR NR ND
DNAH9 #26 17 11840674 Cpd Het Missense I2671M 0.001307 NR rs143953217 ND
EIF4E1B #20 5 176072210 Homozygous Missense R147H 0.003643 0.0023 rs115365515 Up****
GORASP1 #19 3 39140352 Cpd Het Missense D162Y 0.00692 0.01 rs13886448 Up***
GORASP1 #19 3 39142562 Cpd Het Missense A127V 0.004306 0.0037 rs61743223 Up***
GTF3C2 #20 2 27558834 Homozygous Missense L473V 0.002537 0.0005 rs148867164 Down*
HENMT1 #13 1 109193733 Homozygous Missense E166A 0.000461 0.0009 rs144705350 Up**
KIAA1755 #12 20 36848055 Homozygous Missense R845C 0.000384 NR rs144671254 Up*
LBP #14 20 36978016 Cpd Het Missense G64R NR NR NR ND
LBP #14 20 36979309 Cpd Het Missense V112D 0.000538 0.0005 rs138570528 ND
MYO3B #42 2 171356232 Cpd Het Missense Q1067R 0.000248 0.0005 rs200292179 ND
MYO3B #42 2 171400401 Cpd Het Splice site None NR NR NR ND
RAB25 #20 1 156035717 Homozygous Missense E20G 0.005891 0.01 rs61751627 Down****
SERPINA10 #15 14 94750486 Cpd Het Missense Q384R 0.008304 0.0037 rs2232710 Down*
SERPINA10 #15 14 94756669 Cpd Het Nonsense R88X 0.005305 0.0032 rs2232698 Down*
SPTB #11 14 65253667 Cpd Het Missense A1006T 0.001153 NR rs151112486 ND
SPTB #11 14 65267517 Cpd Het Missense S278F NR NR NR ND
TAF1L #39 9 32631781 Homozygous Missense P1266R 0.002076 NR rs140558556 NR
TF #30 3 133496032 Homozygous Missense G671E 0.003691 0.0032 rs121918677 Up****
THSD7B #22 2 138373831 Homozygous Missense Q1141H 0.004745 0.0009 rs150657202 ND
USH2A #05 1 215844468 Cpd Het Missense P4660L NR NR NR ND
USH2A #05 1 216420214 Cpd Het Missense S841Y 0.005305 0.0027 rs111033282 ND
WDR6 #36 3 49049385 Cpd Het Missense L140V NR NR NR ND
WDR6 #36 3 49050499 Cpd Het Missense R460H 0.000846 0.0009 rs142520902 ND
The minor allele frequencies from the NHLBI Exome Sequencing Project (ESP) and 1000 Genomes Project (1KG) projects and the dbSNP137 rsID are provided. Differential expression of each gene in the
spinal cord compared to non-central nervous system tissue from11 is noted. Cpd Het: compound heterozygous. ND: no difference, NR: not reported,*: p, 1022, **: p, 1024, ***: p, 1026, ****: p,
10210.
www.nature.com/scientificreports
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Functional implications.All except one (HENMT1) of the recessive
variants were accepted in the DAVID functional annotation analysis.
This analysis revealed an enrichment of genes sharing the domain-1
of dynein heavy chain (DNAH10, DNAH2 and DNAH9) (p 5
0.00006, FDR 5 0.004). In addition, the above three genes, along
withABCA2 and ATP8B3 (all five genes with ATPase activity and an
ATPase-associated domain) were enriched (p 5 0.0023, FDR 5
0.058). The above five variants also have nucleotide binding
capacity, together with CNGA4, MYO3B and RAB25 (p 5 0.0025,
FDR 5 0.07). Therefore of these eight genes, all have nucleotide
binding capacity, five have ATPase activity, and three have dynein
heavy chain domain-1 activity.
Among the 17 genes with de novo non-synonymous or splicing
variants,METTL22 was not present in the DAVID identification list
and was excluded from the analysis. Within the remaining 16 genes,
seven (LIMD1, FOXN3, GTF2H4,MLL3, STK36, SND1 and TRRAP)
are related to regulation of transcription (p , 0.02, FDR , 0.1).
Another enriched group, comprising ANAPC7, FOXN3 and
PSMB7, is involved in cell cycle processes (p , 0.05, FDR , 0.1).
Our DAVID analyses showed no involvement in any functional
pathways of genes containing either recessive or de novo variants.
The previous ALS trio exome study of Chesi et al., on the other hand,
which used the sameDAVID analysis, reported that chromatin regu-
lator genes were significantly enriched10. When we combined our
and the Chesi et al. de novo variants, and submitted them to func-
tional annotation analysis, genes related to transcription regulation
became more significantly enriched than our previous analysis (p5
0.000032, FDR 5 0.0018). These 15 enriched genes comprised six
from our ALSTRIO list (LIMD1, FOXN3, GTF2H4, MLL3, SND1 and
TRRAP) and nine from the Chesi et al. list (CNOT1, ELL, FOXA1,
FOXK1, HDAC10, SRCAP, SS18L1, ZNF410, ZNF778). This com-
bined analysis therefore gives further weight to the suggestion that
disturbances by de novo variants of transcription regulation genes
may be a pathogenetic mechanism in ALS. On the other hand, genes
related to chromatin modification were not significant in the com-
bined de novo analysis, with a high false discovery rate (FDR5 0.27).
Discussion
Due to the late age of onset of ALS, and the possibility of incomplete
penetrance, it is difficult to assess whether SALS is truly sporadic. For
example, multiple system atrophy was once thought to be sporadic,
but recently-identified compound heterozygous and recessive
mutations in COQ2 segregate with the disease, and heterozygous
mutations in the same gene predispose individuals to this disease13.
Additionally, it has been reported that ALS patients harbour a greater
number of rare homozygous segments than controls, and that these
segments are longer and contain more genes4. This suggested further
evidence for a recessive cause for apparently sporadic ALS, though
our finding of no excess homozygosity in ALS patients does not
support this hypothesis of long runs of homozygosity containing rare
ALS susceptibility variants. This does not necessarily mean that
recessive inheritance can be ruled out, just that long runs of homo-
zygosity were not found in our cohort.
With our dataset of case-parent trios we tested the hypothesis that
rare, recessive-acting variants could contribute to disease susceptibil-
ity. Indeed, a number of promising candidate genes with recessive or
compound heterozygous variants were identified. For example, in
one family we identified two extremely rare variants in ABCA2 that
are highly conserved and are predicted to be damaging. ABCA2
encodes an ATP-binding cassette transporter and plays a role in
intracellular sterol trafficking. It is highly expressed in the brain
and regulates low-density lipoproteinmetabolism in neuronal cells14.
Dysregulation of ABCA2 is associated with amyloid beta deposition
in Alzheimer’s disease15, and ABCA2 null mice accumulate more
gangliosides and sphingomyelin in neuronal tissue compared to
wild-type mice16.
We identified a recessive variant in RAB25 in one ALSTRIO patient.
This gene encodes a protein involved in membrane trafficking and
has nucleotide binding capacity. A meta-analysis of genome-wide
association studies showed that a common variant at the SYT11/
RAB25 locus is associated with Parkinson’s disease in Caucasians17,
suggesting a role for this gene in neurodegenerative diseases.
CACNA1H encodes a protein in the voltage-dependent calcium
channel complex, and we identified two extremely rare damaging
variants inherited as a compound heterozygote in one ALSTRIO
patient. Dysregulation of calcium homeostasis in spinal and motor
neurons has been previously demonstrated in mouse models of
ALS18. This leads to altered excitability of motor neurons with modi-
fied synaptic activity and neuronal excitotoxicity19. Of interest, in
presymptomatic ALS patients cortical hyperexcitability appears to
Table 3 | Rare coding de novo variants in ALS trio patients












AKD1 #08 6 109894726 Missense E755K NR NR NR Yes Up**
ANAPC7 #21 12 110819574 Missense R108H NR NR NR Yes Down**
CHRM1 #41 11 62678572 Missense,
initiator codon
M1V NR NR NR Yes Down*
FOXN3 #30 14 89656737 Nonsense Q119X NR NR NR Yes Down*
GTF2H4 #35 6 30880156 Missense R337Q 0.010308 0.01 rs3218820 No NR
ITPR2 #42 12 26808680 Missense F850L NR NR NR Yes Up****
LIMD1 #02 3 45637047 Missense P226S NR NR NR Yes Down**
METTL22 #30 16 8738455 Missense A295V NR NR NR Yes Down**
MLL3 #02 7 151849993 Missense R234Q NR NR NR Yes Down*
NLRC5 #43 16 57073761 Missense,
splice site
R256M NR NR NR Yes Down**
PLA2G4C #24 19 48607867 Missense A79S NR NR rs13895674 No Up***
PSMB7 #08 9 127119118 Missense I216T NR NR NR Yes Down***
RINL #10 19 39359972 Missense R404Q NR NR NR Yes NR
SND1 #24 7 127341354 Missense S179L NR NR rs24667910 No ND
STK36 #14 2 219538460 Missense M12R NR NR NR Yes Down*
SV2A #20 1 149885128 Missense E89K NR NR NR Yes Up****
TRRAP #35 7 98553842 Missense S1977N NR NR NR Yes ND
The minor allele frequencies from the NHLBI Exome Sequencing Project (ESP) and 1000 Genomes Project (1 KG) projects and the dbSNP137 rsID are provided. Differential expression of each gene in the
spinal cord compared to non-central nervous system tissue from11 is noted. ND: no difference, NR: not reported,*: p , 1022, **: p , 1024, ***: p , 1026, ****: p , 10210.
www.nature.com/scientificreports
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be an early feature20. Our results give more weight to the idea that
variants in voltage-dependent calcium channel genes play a role in
ALS susceptibility.
Functional annotation analysis of the recessive variants showed
enrichment for genes that are involved in the dynein heavy chain
(DNAH10, DNAH2 and DNAH9). This is of interest since defects in
axonal transport have long been suspected to play a part in ALS21. A
group of five genes, comprising the three dynein-related genes above,
as well as ABCA2 and ATP8B3, were enriched for ATPase activity.
Na,K-ATPase has been suggested to be involved in mutant-SOD1
ALS22, but data on the activity of other forms of APTase in ALS are
sparse, despite the fact that altered energy metabolism is a possible
mechanism in ALS23. Finally, the above five genes, as well as a further
three (CNGA4, MYO3B and RAB25) are enriched for nucleotide
binding activity. Of note, caution needs to be exercised in attributing
importance to the variants in DNAH10 and MYO3B since exome
sequencing frequently finds variants in these genes24.
Recent studies of individual SALS patients and their parents have
identified de novo variants inALS-associated genes such as FUS25 and
CREST26. Other sporadic disorders such as autism spectrum disorder
demonstrate a similar pattern of recurrent de novo variants27.
Interestingly, we identified a novel de novo initiator codon variant
in CHRM1, a gene that also harbored a de novomissense variant in a
previous ALS exome trio study10. This gene encodes a cholinergic
receptor and is predicted to be involved in diseases of motor neurons
and frontotemporal dementia, which is related to ALS. CHRM1 is
predominantly expressed in the parasympathetic nervous system
and influences the effects of acetylcholine in the central and peri-
pheral nervous systems. In patients with Alzheimer’s disease, loss of
CHRM1 exacerbates cognitive decline28 and increases amyloid
pathology29. In spinal cord injuries significantly reduced gene
expression ofmuscarinic cholinergic receptors intensifies motor dys-
function30. Our results further support the hypothesis that damaging
variants in CHRM1 contribute to neurodegenerative disorders such
as ALS.
Of note, CHRM1 was the only gene in which de novo variants (in
different regions of the gene) were found in both our and the pre-
vious ALS trio exome study of Chesi et al.10, with the two studies
containing a total of 91 ALS patients. This implies that, if de novo
mutations do play a major part in ALS, large numbers of private
mutations in different genes are likely to be responsible for the
disease.
We identified a novel coding de novo variant in ITPR2. Common
variations in this gene have been associated with ALS, with the
expression of ITPR2 being increased in the peripheral blood of
ALS patients31. ITPR2 is highly expressed in motor neurons where
it encodes a calcium channel on the endoplasmic reticulum, the latter
a site a great interest in ALS32. Dysfunction of ITPR2 with increased
intracellular calcium may lead to motor neuron cell death31 and
overexpression of murine ITPR2 in the SOD1G93A ALS mouse model
damages cells by increasing the release of neuronal calcium33. In
neuronal cell lines, oxidative stress leads to calcium dysregulation
by upregulating ITPR2 expression, which increases calcium release
into the nucleus34. The association of ITPR2 with ALS has not been
replicated in other genome-wide association35 or single nucleotide
variant studies, though these only assayed common, and not rare,
variants. Our results, on the other hand, suggest that rare variants in
this gene may contribute to the pathogenesis of ALS.
Functional annotation analysis of our de novo variants showed
seven that are related to transcription regulation (LIMD1, FOXN3,
GTF2H4,MLL3, STK36, SND1 andTRRAP), which is in keepingwith
the findings of abnormal RNA transcription and processing inALS36.
Caution though needs to be exercised attributing significance to the
de novo variant found in STK36 since this gene frequently contains
variants in exome sequencing24. The finding of de novo variants in
three genes related to the cell cycle (ANAPC7, FOXN3 and PSMB7) is
in accord with suggestions that cell cycle abnormalities underlie
some instances of ALS37.
It has been suggested that ALS may be caused by variants in a
number of genes within one individual, the so-called oligogenic
hypothesis38. Our findings support this hypothesis, since nine
ALSTRIO patients had more than one gene with either a recessive or
de novo rare variant. The Poisson distribution for novel de novo
coding variants in our study suggests that these variants alone are
unlikely to be involved in an oligogenic process. However, 75% of our
ALS patients who had de novo variants had concurrent recessive or
other de novo variants; only 3 patients had a single de novo variant,
and in these it is quite possible that other recessive or de novo variants
outside of the exome sequencing targets could play contributory
roles.
Although evidence for an oligogenic mechanism for ALS was
present in our present study, we looked only at single nucleotide
variants. Other genetic abnormalities, such as copy number variants,
DNA methylation39, or somatic mutations40 could interact with the
variants we found in our ALSTRIO patients to confer further suscept-
ibility to disease. For example, when 12 of the present ALSTRIO
patients had genome-wide CNVs analysed with microarrays in a
previous study40, de novo CNVs were found in 11 of them
(Table 1). CNVs that overlappedwith genes or promoters were found
in eight of these patients, including three with multiple CNVs.
ALS trio studies are uncommon, and without access to parent
DNA we do not know how many mutation-carrying parents of
ALS patients never develop the disease, or develop it at a much older
age than their offspring. ALS-associated variants were found in our
study in four ALSTRIO patients as well as in an unaffected parent; one
of these was in SOD1, two in C9orf72, and one in TDP-4341. Either
environmental or modifying genetic variations could be responsible
for this difference in phenotype between parent and offspring.
Unaffected mutation-bearing parents could also carry a protective
genetic variant elsewhere in their genomes. Our finding that all four
of the above ALSTRIO patients had additional single nucleotide or
copy number variants suggests that other genetic variants may be
needed for the ALS phenotype to appear in some patients who have
apparently single gene mutations.
Limitations of the present study are: (1) Our ALS patients had a
younger average age of onset that is usual for this disease, so they
could represent a different subgroup where genetic variants are more
common than inmost sporadic ALS. (2) A parent could present with
the onset of ALS much later in life (a not uncommon clinical scen-
ario), so we cannot be sure that the ALS in our trios was truly of an
isolated/sporadic nature. (3) We did not analyse the whole genome,
so potentially significant recessive or de novo variants in intronic or
intergenic regions could not be detected. (4) Further assessment of
compound heterozygote and de novo variant frequency in ALS will
only be able to be undertaken once larger numbers of ALS trios
become available, which will require an international collaborative
effort. A number of groups are presently undertaking exome sequen-
cing on large numbers of individual ALS patients, so whether the
variants we found are truly private mutations or are more common
will soon be known. Not having parental DNA, however, means
these studies will not be able to determine whether the variants are
actually recessive or de novo in nature. (5) Exome capture is inher-
ently biased towards the creation of false positives. For this reason we
imposed several quality control steps in an attempt to filter out false
positives. For the de novo variants we used Polymutt software that
takes into account the parental genotypes when calling a de novo
variant in the offspring. Of the variants that did not validate, 14 were
due to poor Sanger data quality in one or both of the parents and four
were due to poor Sanger data quality in the offspring. Seven variants
were actually homozygous reference in the child and two variants
were present (but undercalled from exome data) in the parents,
representing true false positives. Although there are slightly more
www.nature.com/scientificreports
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de novo variants than would be expected from a true exome (,1 per
family), most of these were non-coding or silent mutations. There
were only 17 coding (15 missense) de novo variants out of the 44
families; this number is in line with de novo coding events in other
exome studies42. (6) Because of our relatively small number of trios,
we did not have sufficient numbers to undertake a rare variant trans-
mission disequilibrium test (TDT) that would yield adequate statist-
ical power43,44.
As is common in other genomics-based studies, we expect that the
variants we found will be a springboard for other researchers to
develop model systems to further explore their functionality. We
consider all our 28 recessive and 17 de novo variants to be strong
candidates for a role in ALS, since our vigorous in silico analyses
ensured that we reported only validated variants that are rare and
involved in processes or metabolic pathways implicated in ALS.
Complex model systems will be needed to test the functionality of
these variants, since testing has to take into account the probability
that multiple variants are acting together, and that exposure to envir-
onmental toxins, such as heavy metals45 and neurotoxic amino
acids46, are also playing a part in the disease. Future studies using a
combination of whole genome nucleotide sequences, structural var-
iations, and epigenetic differences, using multiple tissues to look for
somatic mutations, and obtaining DNA from multiple generations,
are likely to be needed to uncover all the variants comprising the
genetic contribution to sporadic ALS.
In conclusion, our exome sequencing of ALS-unaffected-parents
trios has uncovered rare homozygous, compound heterozygous, and
de novo variants that are likely to play a role in the pathogenesis of
this disease. Most of these appear to be private variations, which
implies that we will be unlikely to find any more mutations (such
as those in C9orf72) that are common to large numbers of sporadic
ALS patients. The implications of this study are four-fold: firstly,
there are no previously published ALS trio exome studies showing
the widespread occurrence of potentially deleterious compound het-
erozygous variants. Secondly, only one previous ALS trio study has
demonstrated de novo variants, and our study confirmed these do
occur, though in different genes (apart from one shared between the
two studies), indicating that most are likely to be rare or private
variants. Thirdly, we validated extremely rare, highly conserved,
deleterious recessive mutations in our sporadic ALS patients.
Hidden recessive inheritance in ALS has been hypothesised formany
years, and we have now been able to show the importance of this
mode of inheritance that could explain the sporadic nature of some
ALS, possibly in combination with other recessive or de novo var-
iants. Finally, our findings give the best evidence so far that oligo-
genic variants underlie much of sporadic ALS.
Methods
Ethics statement. The study protocol was approved by the Sydney South West Area
Health Service Human Research Ethics Committee. Informed written consent was
obtained from each individual for their DNA to be used for research purposes. All
methods were carried out in accordance with the approved guidelines and
regulations.
SALS patients and unaffected parents. Individuals selected for study were patients
with ALS who had donated blood samples to the Australian Motor Neuron Disease
DNA Bank, and whose ALS-unaffected parents had also given blood samples to the
Bank. The diagnosis of ALS wasmade by a neurologist using standard criteria. For the
purpose of this study, patients were considered to have ‘‘sporadic’’ ALS if they had no
history of ALS in any family member at the time of blood sampling, even if an ALS-
associated mutation was found in that patient and their family member. All ALS
offspring in this study are referred to as ‘‘ALS Trio’’ (ALSTRIO) patients.
Exome sequencing. For details of exome sequencing see Supplementary Methods
online, and for sequencing metrics see Supplementary Table S6 online.
Variant calling and annotation pipelines. Figure 1 outlines the methods used to
filter the exome variant calls to detect autosomal recessive, compound heterozygous,
and de novo variants in the ALS offspring of the trios. For details of variant calling and
annotation pipelines see Supplementary Methods online.
Validation of variants. For details of the method to validate the variants see
Supplementary Methods online.
ALSoD analysis. Data from the ALS online database (http://alsod.iop.kcl.ac.uk/)
were downloaded, and variant calls from the exomes were intersected with the
previously identified ALS susceptibility variants. The affected and unaffected carrier
frequencies were calculated using GEMINI, a framework for exploring genome
variation.
Homozygous segments. Thirty of 44 ALS probands were genotyped on the Illumina
Human Omni Express Bead Chip. Control data were drawn from the 379 European
descent 1000 Genomes individuals that were genotyped on the Illumina Omni 2.5
Bead Chip. Data for both sets were imported into the whole genome analysis tool
PLINK (v.1.07)47 and standard quality control procedures were applied. Samples were
excluded if they had call rates,95%, single nucleotide polymorphisms (SNPs) with
minor allele frequencies, 0.01, Hardy-Weinberg equilibrium p-values, 0.0001, or
non-random missingness in cases versus controls. The two datasets were combined
and the intersection of the two marker lists was used for a total of 667,708 SNPs
genome-wide. SNPs were pruned based on linkage disequilibrium using a ‘‘light’’
pruning scheme48, where SNPs with r2 . 0.9 in a 50 SNP window were removed,
leaving 307,288 SNPs. In addition, none of the cases were outliers from the 1000
Genomes European ancestry populations based on PLINK multidimensional scaling
analysis. Runs of homozygosity (segments .2 Mb) were identified from the
autosomal chromosomes in PLINK4 and burden and association analyses were
performed as previously described4, with the exception that the gene list was taken
from the UCSC Table Browser hg19 RefSeq genes. Briefly, homozygous segments
were coded as copy number variants and analyzed using the PLINK rare copy number
variant burden and association analysis. p-values were generated from 100,000 case/
control permutations and statistical significance was set at a genome-wide corrected
p-value , 0.05.
Functional implications. To predict the functional implications of the identified
variants, lists of de novo and recessive variants were generated from the exome
sequencing data and submitted to the Database for Annotation, Visualization and
Integrated Discovery (DAVID 6.7)49. The NimbleGen SeqCap EZ Human Exome
gene list was used as a background. Potential functional enrichments and pathway
analysis were explored, with p-values, 0.05 and false discovery rates, 0.1 selected
as significant. Pathway analysis was also undertaken on the combined de novo variant
findings in our and in the Chesi et al. ALS trio exome study10.
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